What is the Difference Between Imipenem and Meropenem?

🆚 Go to Comparative Table 🆚

Imipenem and meropenem are both carbapenem antibiotics, which are broad-spectrum antibacterial drugs. They were introduced to the market in 1987 and 1996, respectively. While they share some similarities, there are differences between the two in terms of their activity against various bacteria, pharmacokinetics, and adverse effects.

  1. Activity against bacteria: In general, imipenem is more active against Gram-positive cocci, while meropenem is more active against Gram-negative bacilli. However, both drugs display similar activity against most bacteria.
  2. Pharmacokinetics: The agents have similar pharmacokinetics.
  3. Clinical efficacy: Clinical trials comparing imipenem with meropenem have reported no significant differences between the two in terms of clinical cure rates.
  4. Adverse effects: Meropenem is preferred for daily use in healthcare services when carbapenems are to be used due to its milder adverse effects. Imipenem's stability does not allow for long infusions, and its main adverse effect is on the central nervous system.

In conclusion, both imipenem and meropenem are effective antibiotics with similar pharmacokinetics and clinical efficacy. However, meropenem is preferred for daily use in healthcare services because of its milder adverse effects and greater activity against Gram-negative bacilli.

Comparative Table: Imipenem vs Meropenem

Imipenem and meropenem are both antibiotics belonging to the carbapenem family, used to treat bacterial infections. However, there are some differences between the two:

Property Imipenem Meropenem
Activity More active against Gram-positive cocci More active against Gram-negative bacilli
Spectrum Weaker activity against Enterobacteriaceae, Escherichia coli, and Pseudomonas aeruginosa Stronger activity against Enterobacteriaceae, Escherichia coli, and Pseudomonas aeruginosa
Patent First patented in 1975 First patented in 1983
Approval Approved for medical use in the United States in 1987 Approved for medical use in the United States in 1996
Related Compound Cilastatin Not applicable

In general, imipenem is more effective against Gram-positive cocci, while meropenem is more effective against Gram-negative bacilli. Meropenem is also more active against Enterobacteriaceae, Escherichia coli, and Pseudomonas aeruginosa compared to imipenem. Both antibiotics can be administrated intravenously and have similar pharmacokinetics.